{"disease":{"id":"scid","name":"scid"},"drugs":{"marketed":[{"drug_id":"elapegademase","indication_name":"Adenosine deaminase severe combined immune deficiency (ADA-SCID)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."},{"drug_id":"elapegademase","indication_name":"SCID due to absent adenosine deaminase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00128973","title":"Evaluation of Patients With Immune Function Abnormalities","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT01953016","title":"Participation in a Research Registry for Immune Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":716,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT00006319","title":"Molecular and Clinical Studies of Primary Immunodeficiency Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":266,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04225962","title":"Intimacy of Women With Cystic Fibrosis","phase":"","overall_status":"COMPLETED","enrollment_count":211,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07314229","title":"Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":130,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06659588","title":"Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03584841","title":"Implementation of a Non-invasive Version of the Imaging β-adrenergic-dependent Sweat Secretion Test","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT03653377","title":"Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03619551","title":"Conditioning SCID Infants Diagnosed Early","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT01852071","title":"Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT01306019","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT01380990","title":"Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":true},{"nct_id":"NCT02963064","title":"JSP191 Antibody Targeting Conditioning in SCID Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Jasper Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06851767","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":18,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03879876","title":"Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03217617","title":"SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT03645460","title":"Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT01420627","title":"EZN-2279 in Patients With ADA-SCID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Leadiant Biosciences, Inc.","has_results":true},{"nct_id":"NCT02022696","title":"Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04370795","title":"Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT01182857","title":"Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}